Literature DB >> 32362622

Differential diagnosis of non-small cell lung carcinoma by circulating microRNA.

Anjana Singh1, Ravi Kant1, Tajindra Singh Saluja2, Tanya Tripathi2, Kamini Srivastava2, Manisha Naithani1, Anurag Gupta2, Anissa Atif Mirza1, Ved Prakash3, Satyendra Kumar Singh2.   

Abstract

INTRODUCTION: More than 70% of lung cancer comprises nonsmall-cell lung carcinoma and is associated with poor survival outcome owing to late diagnosis. Identification of lung cancer in early stages when no clinical signs or symptoms are evident, can drastically improve the prognosis. To this end, we aimed to evaluate the changes occurring at tissue level by assessing the expression of six microRNAs (miRNAs) in lung adenocarcinoma (AC) and squamous cell carcinoma (SCC).
MATERIALS AND METHODS: Peripheral blood of histopathologically proven cases of lung AC and SCC was collected and processed for the isolation of miRNAs using commercially available kit. Primers against mir-2114, mir-2115, mir-2116, mir-2117, mir-449c, and mir-548q with loading control Caenorhabditis elegans were used. Screening was carried out in thirty cases of both AC and SCC, whereas twenty healthy controls were included.
RESULTS: Real-time polymerase chain reaction data revealed that the expression of mir-2114 and mir-449c in AC and mir-2115 in SCC was significantly upregulated. The expression of these miRNAs was also confirmed in lung AC cell line. The differential pattern of expression of these miRNAs can be used for precise diagnosis of lung carcinoma.
CONCLUSIONS: We have used a noninvasive technique to identify the subtype of lung cancer based on molecular genetic signatures. The results suggest that through molecular profiling of miRNA, we can screen high-risk cases for cancer interception.

Entities:  

Keywords:  MicroRNA; molecular diagnosis; nonsmall-cell lung cancer; real-time polymerase chain reaction

Mesh:

Substances:

Year:  2020        PMID: 32362622     DOI: 10.4103/jcrt.JCRT_872_19

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  6 in total

1.  Clinical Efficacy of Osimertinib in Patients with Advanced Non-Small Cell Lung Cancer and Its Effect on Serum CEA and VEGF Expression.

Authors:  Huanyuan Wang; Xiangwu Zhou; Zhaozhen Wang; Tianzhu Lu; Baoliang Li; Sicong Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-25       Impact factor: 2.650

Review 2.  The Impact of Air Pollution Exposure on the MicroRNA Machinery and Lung Cancer Development.

Authors:  Michal Sima; Andrea Rossnerova; Zuzana Simova; Pavel Rossner
Journal:  J Pers Med       Date:  2021-01-19

Review 3.  MicroRNAs and Metabolism: Revisiting the Warburg Effect with Emphasis on Epigenetic Background and Clinical Applications.

Authors:  Zsuzsanna Gaál
Journal:  Biomolecules       Date:  2021-10-17

4.  Research on the application of uniportal video-assisted thoracoscopic segmental resection of the lung in elderly patients with non-small cell lung cancer aged over 65 years.

Authors:  Hongya Xie; Jinxing Tang; Donglin Zhu; Guangda Yuan; Tengteng Wei; Xiaoqiang Liu; Yong Yang
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2021-06-04       Impact factor: 1.195

5.  Analysis of miR-375-3p, miR-197-3p, and miR-15a-5p Expression and Their Clinical Relevance as Biomarkers in Lung Cancer.

Authors:  Sachin Kumar; Jyoutishman Saikia; Surender K Sharawat; Prabhat S Malik; Sunil Kumar; Anant Mohan
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

6.  Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with "Oncogene-Addicted" Advanced Lung Adenocarcinoma: A Real-World Clinical Study.

Authors:  Laura Lupini; Roberta Roncarati; Lorenzo Belluomini; Federica Lancia; Cristian Bassi; Lucilla D'Abundo; Angelo Michilli; Paola Guerriero; Alessandra Fasano; Elisa Tiberi; Andrea Salamone; Donato Michele Cosi; Elena Saccenti; Valentina Tagliatti; Iva Maestri; Silvia Sabbioni; Stefano Volinia; Roberta Gafà; Giovanni Lanza; Antonio Frassoldati; Massimo Negrini
Journal:  Int J Mol Sci       Date:  2022-08-01       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.